Pages
Products

PARP


Official Full Name
Poly (ADP-ribose) polymerase
Synonyms
Poly (ADP-ribose) polymerase; PARP

Cat.No. Product Name Price
SHW005758 shRNA set against Chicken PARP1 (NM_205263) Inquiry
SHR088494 shRNA set against Human PARP1(NM_001618.3) Inquiry
SHG189331 shRNA set against Human COL11A2(NM_080680.2) Inquiry
SHR088458 shRNA set against Mouse Parp1(NM_007415.2) Inquiry
SHH370820 shRNA set against Rat PARP1 (NM_013063.2) Inquiry
SHH370816 shRNA set against Mouse PARP1 (NM_007415.2) Inquiry
SHW009926 shRNA set against Danio rerio PARP1 (NM_001044942) Inquiry
SHG189217 shRNA set against Human COL11A2(NM_080681.2) Inquiry
SHR088476 shRNA set against Rat Parp1(NM_013063.2) Inquiry
SHR064698 shRNA set against Rat Olr515_predicted(NM_001000315.1) Inquiry
SHH370812 shRNA set against Human PARP1 (NM_001618.3) Inquiry
SHH370804 shRNA set against Mouse PARP (NM_030253.3) Inquiry
SHH370800 shRNA set against Human PARP (NM_031458.2) Inquiry
SHH365080 shRNA set against Rat Olr516 (NM_001000316.1) Inquiry
SHH267037 shRNA set against Rat COL11A2 (NM_212528.1) Inquiry
SHH267033 shRNA set against Mouse COL11A2 (NM_009926.1) Inquiry
SHH267029 shRNA set against Human COL11A2 (NM_080679.2) Inquiry
SHG189295 shRNA set against Mouse Col11a2(NM_009926.1) Inquiry
SHG189277 shRNA set against Rat Col11a2(NM_212528.1) Inquiry
SHG189235 shRNA set against Human COL11A2(NM_080679.2) Inquiry
SHH370808 shRNA set against Rat PARP (NM_001103351.2) Inquiry
SHW010833 shRNA set against Danio rerio COL11A2 (NM_001079992) Inquiry
Cat.No. Product Name Price
CDCB167233 Chicken PARP1 ORF Clone (NM_205263) Inquiry
MiUTR1R-05193 OLR516 miRNA 3'UTR clone Inquiry
MiUTR1R-01106 COL11A2 miRNA 3'UTR clone Inquiry
MiUTR1M-08908 PARP1 miRNA 3'UTR clone Inquiry
MiUTR1M-03192 COL11A2 miRNA 3'UTR clone Inquiry
MiUTR1H-07517 PARP1 miRNA 3'UTR clone Inquiry
MiUTR1H-02300 COL11A2 miRNA 3'UTR clone Inquiry
MiUTR1H-02299 COL11A2 miRNA 3'UTR clone Inquiry
MiUTR1H-02298 COL11A2 miRNA 3'UTR clone Inquiry
CDFR015398 Rat Col11a2 cDNA Clone(NM_212528.1) Inquiry
CDFR010866 Rat Parp1 cDNA Clone(NM_013063.2) Inquiry
CDFR000309 Rat Olr516 cDNA Clone(NM_001000316.1) Inquiry
CDFL002936 Mouse Col11a2 cDNA Clone(NM_009926.1) Inquiry
CDFH004017 Human COL11A2 cDNA Clone(NM_001163771.1) Inquiry
SKO0656 PARP1 Validated sgRNA vector Inquiry
CDCL185612 Mouse PARP1 ORF clone(NM_007415.2) Inquiry
CDCL185611 Human PARP1 ORF clone(NM_001618.3) Inquiry
MiUTR1R-05628 PARP1 miRNA 3'UTR clone Inquiry
CDCR377943 Rat Parp1 ORF Clone(NM_013063.2) Inquiry
CDCR367226 Rat Olr516 ORF Clone(NM_001000316.1) Inquiry
CDCR049194 Mouse Col11a2 ORF clone (NM_009926.1) Inquiry
CDCR049192 Human COL11A2 ORF clone (NM_001163771.1) Inquiry
CDCR049190 Human COL11A2 ORF clone (NM_080681.2) Inquiry
CDCR049188 Human COL11A2 ORF clone (NM_080680.2) Inquiry
CDCR049186 Human COL11A2 ORF clone (NM_080679.2) Inquiry
CDCB195611 Rabbit COL11A2 ORF clone (XM_008263250.1) Inquiry
CDCB189408 Rabbit PARP1 ORF clone (XM_008268352.1) Inquiry
CDCB172308 Danio rerio COL11A2 ORF Clone (NM_001079992) Inquiry
CDCB171401 Danio rerio PARP1 ORF Clone (NM_001044942) Inquiry
CDCR382175 Rat Col11a2 ORF Clone(NM_212528.1) Inquiry

Detailed Information

PARP inhibition works as a therapeutic option in Melanoma treatment

PARP inhibition and immunotherapy were used in the treatment of melanomas, which have homologous recombination DNA damage repair pathways. In the treatment of cancers with BRCA mutation, PARP inhibition has been established to be therapy through synthetic lethality. More than this, in the treatment of other types of homologous recombination defects, it has also been found to have some applications. In 20%-40% of cutaneous melanoma, PARP gene was found to be mutated. Despite the transformation brought out by the immunotherapy used in the treatment of melanoma to get improvements in patient outcomes, the issue of resistance and tumor escape of this monotherapy remains to be unresolved. So, new therapies, combination strategies and biomarker-guided decision making are desired to be made to benefit from treatment. For example, the application of PARP inhibition has been extended to the treatment of melanoma, which is classified into the BRCA-negative cancers with high rate of DNA damage repair pathway mutations. The therapeutic effect of PARP inhibition in combination with immunotherapy can be augmented through multi-faceted immune-priming capabilities.

Future perspectives of PARP applications

The combination of PARP and immune checkpoint inhibitor therapy was demonstrated to be with a synergistic effect in the cell line and preclinical experiments, double-strand DNA breaks induced by the PARP inhibition through the cGAS-STING pathway can give rise to genomic instability, which can increase tumor burden and induce immunogenicity. Inflammation, immune priming and upregulation of PD-1 expression can be also promoted by the DNA unrepairing. Those mentioned associations between PARP and the tumor-immune response may indicate that immune checkpoint inhibition can be sensitized by PARP inhibition. There is also an ongoing phase II clinical trial investigating the combination therapy, whose efficacy and safety are needed to determine, for the HR-DDR mutated patients may benefit a lot from it.

The mechanism of the action of PARP inhibitors. Figure 1. The mechanism of the action of PARP inhibitors. (Feiyue Zheng, et al. 2020)

References:

  1. Zheng F, Zhang Y, Chen S, et al. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomedicine & Pharmacotherapy, 2020, 123: 109661.
  2. Chan W Y, Brown L J, Reid L, et al. PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?. Cancers, 2021, 13(18): 4520.
Quick Inquiry